Cryo-Cell and S-Evans Biosciences Expand Strategic Partnership and Research Collaboration Initiatives for Menstrual Blood Stem Cell Technology

Agreement Includes Preclinical Research Study for Type 1 Diabetes

Stem cell collection and cryopreservation company Cryo-Cell International, Inc. has expanded its strategic partnership with China-based S-Evans Biosciences, Inc., a privately-held stem cell and genomics technology company. Similar to the agreement already in place in mainland China, it will allow SEB to market and sell proprietary C’elle menstrual blood stem cell service exclusively throughout Thailand.

Launched in November of 2007, C’elle is the service which enables women to collect and cryopreserve their stem cells from menstrual blood, much like the services of Cryo-Cell and other companies which offer collection and storage of stem cells from umbilical cord blood.

C’elle specimens collected from clients in Thailand will be shipped to SEB’s laboratory in Hangzhou, China for processing and storage. The agreement also provides SEB with the option to obtain a license for C’elle technology should they decide to establish a future laboratory operation in the country.

Cryo-Cell also entered into a strategic research collaboration agreement with SEB to use C’elle menstrual blood stem cell technology for the pre-clinical study of type 1 diabetes. In addition, SEB will initiate research to study the global gene expression of C’elle menstrual blood stem cells in order to gain insights on cell development and differentiation mechanisms. SEB anticipates that this particular study may potentially provide expansive data that may contribute to the possible development of novel therapies that utilize C’elle menstrual blood stem cells to treat a broad range of diseases.

In recent years, there has been a significant surge of progress throughout Southeast Asia associated with the emergence of the biotechnology sector, including stem cell research and experimental stem cell therapies. Stem cell science is in early stages of development in Thailand. In recent years, government initiatives have focused on public education and development of policy and regulation to support and encourage growth of the country’s biotechnology sector. The Thailand National Biotechnology Policy Framework 2004-2009, for example, was established by legislators in late 2003 to promote biotechnology investment and create new bio companies.

"The C’elle menstrual blood stem cell storage service has many unique qualities that include both adult mesenchymal and embryonic stem cell markers which may position this proprietary technology as a compelling potential source for regenerative medicine and for future stem cell therapies," said Dr. Charlie Xiang, CEO of S-Evans Biosciences. "The launch of our research collaboration with Cryo-Cell underscores SEB’s commitment to development of this highly differentiated stem cell technology to potentially treat a broad range of diseases," he added.